First Time Loading...

Global Blood Therapeutics Inc
NASDAQ:GBT

Watchlist Manager
Global Blood Therapeutics Inc Logo
Global Blood Therapeutics Inc
NASDAQ:GBT
Watchlist
Price: 68.49 USD
Updated: May 7, 2024

Global Blood Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Global Blood Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Global Blood Therapeutics Inc
NASDAQ:GBT
Net Income (Common)
-$322.5m
CAGR 3-Years
-18%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$484m
CAGR 3-Years
17%
CAGR 5-Years
-39%
CAGR 10-Years
-20%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Global Blood Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-322.5m USD

Based on the financial report for Jun 30, 2022, Global Blood Therapeutics Inc's Net Income (Common) amounts to -322.5m USD.

What is Global Blood Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-28%

Over the last year, the Net Income (Common) growth was -21%. The average annual Net Income (Common) growth rates for Global Blood Therapeutics Inc have been -18% over the past three years , -28% over the past five years .